HC Wainwright Has Bullish Forecast for TRAX Q2 Earnings

First Tracks Biotherapeutics (NASDAQ:TRAX – Free Report) – Stock analysts at HC Wainwright boosted their Q2 2026 EPS estimates for shares of First Tracks Biotherapeutics in a research report issued to clients and investors on Friday, July 10th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.86) per share for the quarter, up from their previous forecast of ($0.90). HC Wainwright has a “Buy” rating and a $44.00 price objective on the stock. HC Wainwright also issued estimates for First Tracks Biotherapeutics’ FY2029 earnings at ($2.66) EPS and FY2030 earnings at ($1.44) EPS.

Get First Tracks Biotherapeutics alerts:

A number of other analysts have also issued reports on TRAX. Piper Sandler initiated coverage on First Tracks Biotherapeutics in a report on Monday, May 4th. They issued an “overweight” rating and a $54.00 price target for the company. Wedbush started coverage on First Tracks Biotherapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $30.00 target price for the company. JPMorgan Chase & Co. assumed coverage on First Tracks Biotherapeutics in a report on Thursday, April 23rd. They issued an “overweight” rating and a $31.00 target price for the company. Barclays assumed coverage on First Tracks Biotherapeutics in a research report on Wednesday, April 22nd. They set an “overweight” rating and a $40.00 price target on the stock. Finally, Wall Street Zen raised shares of First Tracks Biotherapeutics to a “hold” rating in a research report on Saturday, May 2nd. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, First Tracks Biotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

View Our Latest Research Report on First Tracks Biotherapeutics

First Tracks Biotherapeutics Trading Down 3.4%

Shares of NASDAQ:TRAX opened at $35.01 on Tuesday. The stock has a market capitalization of $1.22 billion and a price-to-earnings ratio of -19.03. The stock’s 50 day moving average is $18.69. First Tracks Biotherapeutics has a one year low of $14.72 and a one year high of $38.49.

Further Reading

• Five stocks we like better than First Tracks Biotherapeutics
• The SK Hynix IPO and 2027’s AI Memory Squeeze
• Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
• Why Welltower’s Growth Story Might Outrun Its Rich Valuation
• One Short- and One Long-Term ETF for Quantum Computing Bulls

Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.